Cell-based immunotherapy represents a new frontier in the treatment of human disease, but one that is maturing rapidly, joining small-molecule drugs and biologics as a third pillar of clinical medicine.


With the advent of new gene-editing tools, improvements in techniques for isolating, activating and expanding specific human cell types, and clinical proof-of-principle established with the first CAR-T cell therapies now seeking global regulatory approval, the dream of individualized cell-based immunotherapies that significantly improve patient outcomes has never been closer to becoming a reality. 


Tmunity Therapeutics was founded to assemble and leverage all the proven talent, tools and insight required to accelerate the delivery of novel T cell therapies to patients, inventing the future of cell therapy today.